Key Takeaways
- First ₹200 crore quarter, all organic: Revenue crossed ₹200 crore for the first time, driven almost entirely organically; acquired API sites contributed only ₹50 lakhs as the transaction closed near quarter-end.
- API business transformed in a single quarter: Organic API revenue grew 85.5% YoY, two acquisitions were completed, and the business was carved into a separate subsidiary with a dedicated CEO, setting up a stated 30%+ CAGR ambition.
- Domestic formulations hit a deliberate air pocket: Reported growth of 11.6% YoY was suppressed by a self-imposed inventory-day reduction and a third-party supply disruption; underlying growth was 15.2%, and both issues were resolved in October.
- Margins held flat while investing for scale: EBITDA margin at 24% vs 24.5% in FY25, as the company absorbed higher employee costs from a hiring catch-up and elevated freight from the West Asia conflict, while simultaneously funding new segment entries.
- What to watch next quarter: Whether the acquired API assets deliver the guided ₹25–30 crore H2 revenue, whether domestic formulations bounce back to the promised 1.5x market growth, and how quickly the Canada OTC launch ramps.
Domestic Formulations: The Inventory & Supply Reset
- Reported vs underlying growth: Q2 revenue grew 11.6% YoY, but management disclosed that without a deliberate 4-day inventory reduction (from 42 to 38 days) and supply challenges from a key third-party manufacturer, growth would have been 15.2%.
- The supply disruption: A key third-party manufacturer faced issues stemming from the West Asia crisis and a US FDA audit, constraining supply during the quarter. The issue was resolved in October, and some lost September sales were already recovered.
- The inventory call: Management reduced channel inventory days from 42 to 38 to strengthen business hygiene and prioritize prescription-led demand over primary stock-pushing, a move it frames as a quality-of-business improvement, not a demand problem.
- Volume tells the real story: Secondary sales volume growth of 6.8%, nearly 2x the market, confirms that underlying prescription demand and patient offtake remain strong.
- Divisionalization complete: The business was split into primary care (general medicine, bone health, pain) and specialty care (nephrology, rheumatology, cardiology, urology), with each basket growing double digits: MAP 24%, nephrology/rheumatology 23%, cardio 18%, immunosuppressants 13%.
- Field force productivity rising: PCPM increased from ₹6.5 lakhs to ₹7.7 lakhs, supported by 100% MR adoption of iPad-based detailing on the upgraded RXR 3.0 app and AI-enabled dashboards.
- Naprosyn crosses ₹100 crore: The flagship brand hit ₹100 crore in secondary sales on a MAT basis, with H1 primary sales of ₹47.9 crore, up 13.6%, driven by Ortho Ignite CMEs engaging 300+ surgeons and Nephrosyn Master Programs for 550+ young surgeons.
- New launches scaling fast: The 12 brands launched in FY26 delivered ₹12.4 crore in H1 revenue, nearly 2x the prior year, with Q2 sales up 50% YoY. The legacy brand Norpace grew 40% in H1.
- Strategic FY27 launches: Naproxen ES (India's first naproxen-esomeprazole combination) already clocked ₹3 crore; Critipenem entered the orthopedic anti-infective space; Flowaxis marked entry into medical devices for nephrology; semaglutide injections launched in October across nephrology and cardiology divisions.
Ashok Nair: "We had almost had a 4-day inventory reduction there. Second, one of our key third-party manufacturers, we almost had supply challenges... However, I'm happy to say that all those things have been cleared in October. In fact, we almost recovered some of the sales which we lost in September due to the supply challenges which we faced. So if you look without that impact, our DF would have been actually at 15.2% growth..."
API: The Quarter Everything Changed
- Organic growth exploded: API revenue grew 85.5% YoY to ₹27.5 crore in Q2, and 57.1% in H1 to ₹54.1 crore, all organically, while management simultaneously executed two acquisitions.
- Structural transformation: The API business was carved out into RPG Active Pharma, an investment from Invasent was brought in, and the acquisition of Actis was announced on 29th July with subsidization effective 14th August. The Raghava (Agua) acquisition was announced on 2nd September; both closed near September-end.
- Manufacturing footprint doubled: The company expanded from 3 to 5 sites: 2 formulation facilities and 3 API facilities across Navi Mumbai, Vishakhapatnam, and Kamaradi near Hyderabad.
- Acquired asset guidance: Management directionally guided ₹25–30 crore of revenue from the acquired entities in H2 FY27, with EBITDA margins in the mid-20s, similar to the existing API business. Full revenue contribution begins Q3.
- The 5-year ambition: Management committed to a 25%+ CAGR in API over 5 years via organic growth and disciplined acquisitions, with a stated target of at least 30% CAGR (organic plus inorganic) over 3–5 years, implying ₹300–350 crore by FY30 and ₹500 crore by FY32, subject to further acquisitions.
- Order book stronger than expected: The order pipeline for the acquired Actis assets has become stronger than initially thought, and the ramp-up for the Raghava plant is set to begin. Organic API is expected to continue double-digit growth.
- US FDA access on the roadmap: Management stated it will look to incorporate US FDA approvals and access to US markets as part of the larger API plan.
Ashok Nair: "If you see our CAGR growth over next 3 to 5 years including both organic and inorganic should be at least 30% for us, which means our API business should at least be at INR300 to INR350 crore by FY30 and INR500 crore by FY32, subject to further acquisitions as well."
International Formulations: The Turnaround Bet
- Returning to growth: International formulations grew 6.4% YoY in Q2 and 7% in H1 after a period of softness, with core franchises performing well. Sodium Valproate grew 38% in South Africa and 17% in Australia.
- The H2 acceleration thesis: Management expects double-digit growth from H2 FY27, citing recent interventions: a new team, CPHI exhibition participation (162 customers met, 75+ discussions with potential partners), tie-ups with 3 Indian R&D players to buy out MAs and dossiers, and a foray into 13 new markets.
- Tenders already converting: Two tenders have been won, with a far better order pipeline for H2. Recent wins span LATAM, Ethiopia, and other markets.
- CDMO gaining traction: Completed projects were delivered on time, and the partner has given 3 additional products to develop.
- Longer-dated revenue visibility: Management expects to add about ₹10 crore of revenue from Chile and Ethiopia from FY29, and the first renewal project in the UK is expected to add about ₹8 crore from FY29. The R&D roadmap targets about ₹25 crore by FY30.
- Canada OTC launch: Social audit approval for Naprosyn was received a week before the call; shipments to Canada start by mid-December. This is RPG's first OTC product globally and only the second product in Canada where the originator is present and RPG is entering. Management expects 25–30% initial market share, citing naproxen's standing as one of the best NSAIDs globally.
Ashok Nair: "First is this will be our first product which will be OTC in the global space. Second, it is the only second product in Canada where the originator is there and we are. So we believe that at least to start off, 25% to 30% of market share to come to us."
Margins & Costs: Investing Through the Cycle
- Margin held near peak: Q2 EBITDA of ₹50.1 crore, a first, with adjusted EBITDA growing 15% YoY. EBITDA margin at 24% compared to 24.5% in FY25, as the company absorbed cost pressures while investing for growth.
- Gross margin expanded 260 bps YoY: Proactive price increases, product mix improvement, strategic inventory securing, cost-saving initiatives, and some FX upside on the dollar front more than offset input cost pressure from the West Asia conflict.
- Employee costs running hot: Employee benefit expenses grew faster than revenue because of three one-time catch-up factors: contractual labour converting to fixed employees, a prior-year headcount freeze being reversed, and field force additions (MRs) for incremental revenue targets. Management stated these costs are now normalized at current levels and output will start showing.
- Freight costs elevated by geopolitics: Other expenses, excluding a one-off ₹5.5 crore, grew faster than revenue mainly due to freight costs (export and domestic) linked to the West Asia war's impact on freight forwarders and supply chains. Normalization depends on the war scenario and crude prices.
- Strategic margin compromise flagged: Management was explicit that entering new segments and ramping new operations will require some compromise on the bottom line, while aspiring to reach back to 25% EBITDA margin. CapEx is expected to remain below 7–8% of sales, with no major change planned beyond acquired assets.
Amol Lone: "Our primary focus is also on the growth. Uh, I mean, when we are doing a lot of activities, uh, towards the growth of the business, I think, uh, we probably will have to compromise little bit on the bottom line because when we are getting into the new segment of the competitors, and there are expenses and there are things which you'll have to do."
Market Position & Competitive Momentum
- Ranking leap: RPG advanced 12 ranks from 62 (March 2025) to 50 in the IPM, becoming the 4th fastest growing company on a MAT basis and the fastest within its covered market.
- 6th straight quarter of market-beating growth: Domestic formulations grew at 11.6% reported, with volume growth of 6.8% nearly doubling market volume growth, reflecting real prescription demand.
- Basket acceleration is broad-based: Every key basket grew double digits and faster than the prior year, with nephrology/rheumatology at 23% and MAP at 24% leading. The new cardiology division grew 18%.
- Brand power scaling: Nephrosyn crossed ₹100 crore in its second year, growing at ~14%, driven by decluttering the business into primary care and specialty care. Mabs brands grew at 24%.
- Trade margin rationalization seen as neutral-to-positive: Management expects no material impact on sales and margins from the new trade margin norms, as selling prices to distributors stay broadly the same while better affordability should bring more patients into treatment, supporting volumes across oncology and specialty portfolios.
Ashok Nair: "Our approach remains one of discipline, cautious optimism, delivering today's commitment while investing in tomorrow's growth."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Acquired API revenue contribution | ₹25–30 crore revenue in H2; EBITDA margin in mid-20s | H2 FY27 |
| API business CAGR | At least 30% (organic + inorganic) | 3–5 years |
| API revenue target | ₹300–350 crore | By FY30 |
| API revenue target | ₹500 crore, subject to further acquisitions | By FY32 |
| Domestic formulations growth | Grow at 1.5x market growth | Coming quarters |
| International formulations growth | Double-digit growth | From H2 FY27 |
| Naprosyn Canada market share | 25–30% initial share | Starting mid-December 2026 |
| International formulations revenue | Add ~₹10 crore from Chile and Ethiopia | From FY29 |
| International formulations revenue | Add ~₹8 crore from UK renewal project | From FY29 |
| International formulations R&D pipeline | Target ~₹25 crore | By FY30 |
| EBITDA margin | Aspire to reach back to ~25% | Ongoing |
| CapEx | Remain below 7–8% of sales | Ongoing |
| Employee costs | Normalized at current level | Going forward |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹211.6 cr, +16.5% YoY; almost entirely organic, acquired sites contributed only ₹50 lakhs |
| Adjusted EBITDA | ₹50.1 cr, +15% YoY; excludes ₹5.5 cr one-time restructuring and acquisition-linked costs |
| Adjusted EBITDA margin | 23.7% (₹50.1 cr on ₹211.6 cr revenue), vs 24.0% in Q2 FY26 (per an analyst's math) |
| Gross margin | Expanded 260 bps YoY, despite West Asia war impact on input costs |
| PBT before exceptional items | ₹42.5 cr, +11.3% YoY |
| H1 FY27 revenue | ₹407.3 cr, +16.2% YoY |
| H1 FY27 adjusted EBITDA | ₹97.9 cr, margin at 24.0%, +16.1% YoY |
| Domestic formulations revenue | ₹145.7 cr, +11.6% YoY; 70% of total revenue; growth would have been 15.2% excluding supply challenges and inventory reduction |
| Domestic formulations volume growth (H1) | 6.8%, almost twice the market growth of 3.4% |
| API business revenue | ₹27.5 cr, +85.5% YoY; entirely organic |
| International formulations revenue | ₹36.7 cr, +6.4% YoY |
| Naprosyn H1 primary sales | ₹47.9 cr, +13.6% YoY; crossed ₹100 cr in secondary sales on a MAT basis |
| FY26 launched brands H1 FY27 sales | ₹12.4 cr, nearly double the ₹6.3 cr in H1 FY26 |
| PCPM (per capita per month) | ₹7.7 lakhs, up from ₹6.5 lakhs last year |
| One-time restructuring and acquisition-linked costs | ₹5.5 cr, impacting reported PBT |
| Acquired API entities H2 FY27 revenue guidance | ₹25–30 cr (directionally), billing commenced Q3 |
| API business CAGR target (organic + inorganic, 3–5 years) | At least 30%, targeting ₹300–350 cr by FY30 and ₹500 cr by FY32 |